Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.

Christina BilliasMegan Langer Sorana G UrsuRebecca Schorr

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)

Multiple myeloma patients receiving chemotherapy without a bone-modifying agent had higher rates of skeletal-related events compared to those being treated with chemotherapy and a bonemodifying agent. Our results highlight the benefit of utilizing bonemodifying agents for the prevention of skeletal-related events in all multiple myeloma patients being treated with chemotherapy.

Keyphrases

multiple myeloma
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
locally advanced
patient reported
bone regeneration